Article Sidebar

PDF
Date Published: 10/03/2021
Abstract Views: 182
Views PDF: 180
DOI: https://doi.org/10.51298/vmj.v498i1.18
Issue
Vol. 498 No. 1 (2021)
Section
Các bài báo
How to Cite
Văn Mão, C., Mạnh Cường, L., & Anh Sơn, H. (2021). NECROSIS EFFECTS OF VACINE-STRAIN MEASLES VIRUS AND NIMOTUZUMAB ON CANCER CELLS. Vietnam Medical Journal, 498(1). https://doi.org/10.51298/vmj.v498i1.18

NECROSIS EFFECTS OF VACINE-STRAIN MEASLES VIRUS AND NIMOTUZUMAB ON CANCER CELLS

Cấn Văn Mão1, Lê Mạnh Cường2, Hồ Anh Sơn1,
1 Học viện Quân y
2 Bệnh viện YHCT Trung ương

Main Article Content

Abstract

Objectives: This study aims to evaluate of necrosis effects of vacine-strain measles virus (MeV) and Nimotuzumab against cancer cells. Materials and methods: MeV and Ninotuzumab were used to induce necrosis on Hep2 cancer cells. Hep2 cells treated with MeV and Nimotuzumab were collected at 48, 72 hours and 96 hours to perform flow cytometry. Results: the proportion of necrosis cells in treated groups was significantly higher than control group. MeV and Nimotuzumab combination induced higher rate of necrosis cells than thouse in single treatment groups. Conclusion: MeV and Nimotuzumab combination increases necrosis on head and neck cancer Hep2 cells than single MeV or Nimotuzumab treatment.

Article Details

Keywords

head and neck squamous-cell carcinoma, measles virus vaccine, Nimotuzumab, necrosis

References

1. Grandis JR T.D. (1993). Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res., 53:3579-3584.
2. Alterio D., Marvaso G., Maffini F., et al. (2017). Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression. Med Oncol., 34(6):107.
3. Sundaram S V.B., Sridharan N and Poojar K. (2015). Nimotuzumab with induction chemotherapy and chemo radiation in patients with advanced head and neck cancer. J Cancer., Ther 6:146 - 152.
4. Nguyễn Thị Thái Hòa (2015). Đánh giá kết quả điều trị kết hợp kháng thể đơn dòng Nimotuzumab - hóa xạ trị ung thư biểu mô vảy vùng đầu cổ giai đoạn lan tràn tại vùng, Luận án tiến sĩ y học, Trường Đại học Y Hà Nội.
5. Galanis E., Atherton P.J., Maurer M.J., et al. (2015). Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res., 75(1):22-30.
6. Russell S.J., Federspiel M.J., Peng K.W., et al. (2014). Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc., 89(7):926-933.
7. Son H.A., Zhang L., Cuong B.K., et al. (2018). Combination of Vaccine-Strain Measles and Mumps Viruses Enhances Oncolytic Activity against Human Solid Malignancies. Cancer Invest., 36(2):106-117.
8. Galanis E., Hartmann L.C., Cliby W.A., et al. (2010). Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res., 70(3):875-882.